Summary
• Crinetics Pharmaceuticals (CRNX) shares surged 18.8% to $55.50 in pre-market trading following a positive product launch announcement.
• The company reported over $5 million in preliminary revenue for its launched product Palsonify and positive results from Phase 2 trials of Atumelnant.
• Analysts maintain a “Buy” rating on CRNX, reflecting confidence in its growth potential following recent developments.
Crinetics Pharmaceuticals, Inc. (CRNX) is experiencing a significant surge, with its current price hitting $55.50, marking an 18.8% increase from the last close of $46.73 in pre-market trading. This notable rise comes on the heels of a recent announcement regarding positive developments related to their product launch and clinical trial results.
Strong Launch Execution and Positive Trial Results Fuel Momentum
Crinetics has unveiled strong preliminary product revenue for its recently launched Palsonify, reporting over $5 million for the fourth quarter of 2025. The company also highlighted that they successfully enrolled over 200 patients for their investigational drug, Atumelnant, in their ongoing Phase 2 trial for Congenital Adrenal Hyperplasia (CAH). Atumelnant demonstrated substantial efficacy by achieving a 67% mean reduction in androgen levels, along with favorable treatment outcomes, as evidenced by 88% of participants reducing glucocorticoid doses to physiologic levels after 12 weeks of treatment.
This announcement, shared shortly before the market opened today, has garnered attention from investors, reflecting confidence in the company’s growth trajectory. Crinetics is scheduled to host an investor conference call today at 8:30 AM ET to further discuss these results and their implications for the company’s future.
Market Performance and Technical Overview
The stock’s recent ascent comes amid noteworthy technical momentum. Currently, CRNX is positioned with a 20-day simple moving average (SMA) deviation of -2.5% and a 50-day SMA at +3.8%. Over the past quarter, the stock has rallied approximately 12.3%, showcasing its potential for recovery after a slight dip of 4.1% for the week. In addition, the stock’s average volume over the past 10 days stands at about 553,711 shares, indicating increased trading activity.
Given the recent surge and the promising results from their clinical trials, investors will be monitoring the stock’s performance closely as it carries substantial momentum into today’s trading session.
Analyst Sentiment and Closing Remarks
Crinetics Pharmaceuticals holds a “Buy” rating from analysts, reflecting positive sentiment toward its expanding product portfolio and successful clinical outcomes. With the latest updates now factored into trading, market participants are likely to focus on the unfolding details during the investor call today.
The stock has made an impressive leap reflecting the enthusiasm around the company’s latest achievements, indicating that traders will be keenly watching how this momentum develops in the next session.